Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CCN2 YAPs at cancer.

Literature DB >> 18766468

CCN2 YAPs at cancer.

Abstract

The YAP transcription coactivator has been implicated as an oncogene and is amplified in human cancers. Previously, it has been shown that CCN2 (connective tissue growth factor, CTGF) is a target of the tumor promoting YAP and its transcription factor target TEAD. A recent report in Genes and Development by Zhao and colleagues (Genes Dev 22:1962-1971 2008) has extended these initial observations to show that CCN2 plays an important role in the growth-promoting function of YAP. These data confirm the role of CCN2 as a key oncogenic mediator. This report briefly summarizes these findings.

Entities: Disease Gene Species

Year: 2008 PMID： 18766468 PMCID： PMC2570011 DOI： 10.1007/s12079-008-0027-1

Source DB: PubMed Journal: J Cell Commun Signal ISSN： 1873-9601 Impact factor: 5.782

14 in total

1. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm.

Authors: A Vassilev; K J Kaneko; H Shu; Y Zhao; M L DePamphilis
Journal: Genes Dev Date: 2001-05-15 Impact factor: 11.361

2. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas.

Authors: Dong Xie; Dong Yin; He-Jing Wang; Gen-Tao Liu; Robert Elashoff; Keith Black; H Phillip Koeffler
Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531

3. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.

Authors: Tsuyoshi Shimo; Satoshi Kubota; Norie Yoshioka; Soichiro Ibaragi; Sachiko Isowa; Takanori Eguchi; Akira Sasaki; Masaharu Takigawa
Journal: J Bone Miner Res Date: 2006-07 Impact factor: 6.741

4. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts.

Authors: Andrew Leask; Alan Holmes; Carol M Black; David J Abraham
Journal: J Biol Chem Date: 2003-02-05 Impact factor: 5.157

Review 5. ETS transcription factors: possible targets for cancer therapy.

Authors: Tsuneyuki Oikawa
Journal: Cancer Sci Date: 2004-08 Impact factor: 6.716

6. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling.

Authors: Yue-Zhen Deng; Ping-Ping Chen; Yan Wang; Dong Yin; H Phillip Koeffler; Baojie Li; Xiang-Jun Tong; Dong Xie
Journal: J Biol Chem Date: 2007-10-21 Impact factor: 5.157

3. Bioscreening and expression of a camel anti-CTGF VHH nanobody and its renaturation by a novel dialysis-dilution method.

Authors: Xiulei Xue; Xiaobo Fan; Qingrong Qu; Guoqiu Wu
Journal: AMB Express Date: 2016-09-13 Impact factor: 3.298

3 in total

CCN2 YAPs at cancer.

1. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm.

2. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas.

3. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.

4. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts.

Review 5. ETS transcription factors: possible targets for cancer therapy.

6. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling.

Review 7. Targeting transcription factors for cancer gene therapy.

Review 8. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?

9. Expression of connective tissue growth factor (CCN2) in desmoplastic small round cell tumour.

10. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer.

Review 1. The CCN2/CTGF interactome: an approach to understanding the versatility of CCN2/CTGF molecular activities.

2. RhoA Ambivalently Controls Prominent Myofibroblast Characteritics by Involving Distinct Signaling Routes.

3. Bioscreening and expression of a camel anti-CTGF VHH nanobody and its renaturation by a novel dialysis-dilution method.